Hosted by Unknown Host · 🇺🇸 US · EN · 63 episodes
Established thought leaders with verified media credentials.
Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COVID outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
Unknown Host hosts The Lancet Respiratory Medicine in conversation with, a health show with 63 episodes published.
Andrew Bush, Heather Zar, Fernando de Benedictis talk about their recent personal view piece where they summarise and discuss the 50-year journey and evolution of inhaled corticosteroids (ICS) in asthma treatment. Click
Anne-Marie Dingemans, Isabelle Opiz, and Corinne Faivre-Finn talk about their multidisciplinary efforts to develop a consensus definition of stage III Non-Small Cell Lung Cancer technical resectability. https://www.thela
Anne Holland and Christine McDonald join Diana Stanley to discuss ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis. Click here to read the full article, Ambulatory oxygen for treatment of ex
Marion Moseby-Knappe talks about a prospective, international, observational biomarker study, within the Targeted Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest (TTM2) trial, to compare four markers
Prof Sailesh Kotecha joins Diana Stanley to discuss the series on reframing prematurity-associated lung disease as a continuum that begins before birth and evolves throughout life. Cick here to read the full series: Look
Dr Neil Greening and Dr Hnin Aung join Diana Stanley to discuss a new multidimensional prognostic risk stratification model for COPD exacerbations. click here to read the full article: https://www.thelancet.com/journals/
Dr Finn McQuaid and Dr Matthew Saunders join Arianna Colosio to discuss an analytical framework to describe potential causal relationships between climate change and tuberculosis. Click here to read the full article Cont
Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fib
Professors Guy Brusselle and Celeste Porsbjerg join us to discuss their recent Series papers on asthma, which will be featured in a cross journal project with The Lancet, published to coincide with a Lancet journal sessi
Diana Stanley, Deputy Editor at The Lancet Respiratory Medicine, is joined by Dr Joan Soriano to discuss a new series on the global epidemiology of respiratory disease, exploring the diagnostic challenges, global trends,
Carole Mitnick & Lorenzo Guglielmetti join Ari Colosio, deputy editor of The Lancet Respiratory Medicine, to discuss the ENDTB-Q trial to evaluate the efficacy and safety of a drug regiment to treat TB in individuals wit
This episode is in Italian. For the English version, please see the main feed. Lorenzo Guglielmetti sul trial clinico ENDTB-Q per valutare l’efficacia e la sicurezza di un regime di farmaci per curare la tubercolosi in i
Deputy editor Ari Colosio speaks with Dr. Laura Garriga-Grimau of the Val d’Hebron Hospital, Autonomous University of Barcelona. Dr. Garriga-Grimau discusses the first multi-country cohort study to describe the clinical
Bianca Brandon is joined by Professor Marcus Schultz and Dr Prashant Nasa to discuss their recent Position Paper reporting insights from an international Delphi expert panel on defining and subphenotyping ARDS. The findi
Bianca Brandon, Senior Editor at The Lancet Respiratory Medicine, is joined by Professor Hjalmar Bouma to discuss a new review on sepsis in immunocompromised patients, exploring the diagnostic challenges, complexities of
Deputy Editor of The Lancet Respiratory Medicine Ari Colosio discusses the critical findings of a new epidemiological study on pulmonary embolism in children and adolescents with Simon Wolf from the University Hospital o
Dr Sandeep Sahay and Professor Franck Rahaghi discuss their Personal View on future treatment paradigms in pulmonary arterial hypertension. Read the full paper, Future treatment paradigms in pulmonary arterial hypertensi
Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM). Continue this conversation on social! Follow
Il Professor Sergio Harari commenta i risultati di un trial clinico di fase 2 volto a valutare l’attivita’ e la sicurezza del farmaco nintedanib come trattamento in pazienti affetti da linfangioleiomiomatosi (LAM). Conti
Dr Robert Kullberg joins us to discuss his Viewpoint on empiric antibiotic therapy for sepsis and the importance of reducing unnecessary use of anti-anaerobic antibiotics. Read the full article: https://www.thelancet.com
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch The Lancet Respiratory Medicine in conversation with, visit https://lancetrespmed.podbean.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent health coverage.
The Lancet Respiratory Medicine in conversation with is hosted by Unknown Host. The show is categorised under health (fitness) and has published 63 episodes.
The Lancet Respiratory Medicine in conversation with has published 63 episodes.
The Lancet Respiratory Medicine in conversation with regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
The Lancet Respiratory Medicine in conversation with is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Lancet Respiratory Medicine in conversation with hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Lancet Respiratory Medicine in conversation with average 14 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Lancet Respiratory Medicine in conversation with's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched today.
